Get the Stockscreener App
1.41
0.00%
0.00
After Hours:
1.38
-0.03
-2.13%
Icecure Medical Ltd stock is traded at $1.41, with a volume of 371.56K.
It is up +0.00% in the last 24 hours and up +13.71% over the past month.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
See More
Previous Close:
$1.41
Open:
$1.44
24h Volume:
371.56K
Relative Volume:
0.77
Market Cap:
$79.76M
Revenue:
$3.67M
Net Income/Loss:
$-13.83M
P/E Ratio:
-5.0357
EPS:
-0.28
Net Cash Flow:
$-10.79M
1W Performance:
+3.68%
1M Performance:
+13.71%
6M Performance:
+96.54%
1Y Performance:
+6.82%
1-Day Range:
$1.32
$1.4799
1-Week Range:
$1.32
$1.66
52-Week Range:
$0.48
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
1.41 | 79.76M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
134.95 | 234.06B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.39 | 154.06B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
387.92 | 148.02B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.17 | 115.71B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.76 | 42.91B | 5.72B | 4.17B | 490.10M | 6.97 |
Icecure Medical Ltd Stock (ICCM) Latest News
IceCure Medical Ltd. Submits Filing for Regulatory Approval of Its Next-Generation XSense? Cryoablation System in Israel - Marketscreener.com
IceCure seeks Israel approval for XSense cryoablation system By Investing.com - Investing.com South Africa
Can IceCure's New Cryoablation System Capture the $174B Minimally Invasive Surgery Market? - StockTitan
A stock that deserves closer examination: Icecure Medical Ltd (ICCM) - US Post News
IceCure Medical Ltd (NASDAQ:ICCM) Sees Significant Drop in Short Interest - Defense World
Short Interest in IceCure Medical Ltd (NASDAQ:ICCM) Decreases By 9.2% - MarketBeat
IceCure Medical Ltd's (NASDAQ:ICCM) Profit Outlook - Yahoo Finance
IceCure gets favorable FDA AdCom vote for ProSense System - MSN
IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates - StreetInsider.com
IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision - PR Newswire
IceCure Medical (NASDAQ:ICCM) Shares Down 1.6%Here's What Happened - MarketBeat
ICCMIceCure Medical Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod - MSN
IceCure submits application to China’s NMPA for cryoablation system approval - Yahoo! Voices
IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China - The Malaysian Reserve
IceCure Medical (NASDAQ:ICCM) Stock Price Down 1.6% – Should You Sell? - Defense World
IceCure Medical Ltd. Files for Regulatory Approval of ProSense Cryoablation System in China - Marketscreener.com
Icecure Medical Announces Equity Distribution Agreement - TipRanks
IceCure Medical Reports Strong Growth and Anticipates FDA Approval in 2025 - TipRanks
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America - Longview News-Journal
IceCure Medical Reports 42% North American Growth as ProSense Cancer Treatment Shows 96% Success Rate - StockTitan
Investors bid IceCure Medical (NASDAQ:ICCM) up US$14m despite increasing losses YoY, taking five-year CAGR to 43% - Simply Wall St
The five-year returns have been enviable for IceCure Medical (NASDAQ:ICCM) shareholders despite underlying losses increasing - Yahoo Finance
Financial Analysis: SANUWAVE Health (OTCMKTS:SNWV) versus IceCure Medical (NASDAQ:ICCM) - Defense World
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule - Kilgore News Herald
IceCure Medical regains full Nasdaq compliance - Medical Buyer
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minim - GuruFocus.com
IceCure Medical Regains Nasdaq Compliance, Securing Market Position - TipRanks
IceCure to Meet Institutional Investors at the H.C. Wainwright a - GuruFocus.com
IceCure Medical regains Nasdaq compliance - Investing.com
IceCure earns European patent win for next-gen cryoablation tech - Mass Device
IceCure Medical Ltd. Receives an Intention to Grant Notice from the European Patent Office - Marketscreener.com
Icecure Nicks Up On European OK For Connector - MENAFN.COM
IceCure Nicks Up on European OK for Connector - Baystreet.ca
European Patent Office Issues Intention to Grant Notice to IceCu - GuruFocus.com
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology - Marketscreener.com
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference - GuruFocus.com
IceCure Medical appoints new board director - Investing.com India
IceCure Medical appoints new board director By Investing.com - Investing.com Australia
Icecure Medical Appoints New Board Director with Financial Expertise - TipRanks
IceCure Medical Ltd Appoints Li Haixiang as Director - Marketscreener.com
IceCure Medical (NASDAQ:ICCM) Stock Price Down 0.4%Here's Why - MarketBeat
IceCure Medical (NASDAQ:ICCM) Shares Down 0.4% – What’s Next? - Defense World
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting - Marketscreener.com
IceCure Medical's ProSense Shows Breakthrough 5-Year Breast Cancer Treatment Results in Major Clinical Trial - StockTitan
Study Published in the British Journal of Radiology Demonstrates - GuruFocus.com
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies - The Eastern Progress Online
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - The Eastern Progress Online
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation - Kilgore News Herald
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery - The Eastern Progress Online
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets - The Eastern Progress Online
Icecure Medical Ltd Stock (ICCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):